VISHEE(SH:688580)2021-10-27 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥111,882,494.11, representing a year-on-year increase of 14.11%[5] - The net profit attributable to shareholders for Q3 2021 was ¥38,391,924.38, reflecting a year-on-year growth of 20.07%[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥32,880,595.77, an increase of 6.50% compared to the same period last year[5] - The net profit attributable to shareholders for the year-to-date period reached ¥107,573,509.85, a 25.66% increase year-on-year[6] - Net profit for the third quarter of 2021 was ¥107,307,555.26, representing a 25.9% increase from ¥85,231,353.21 in Q3 2020[24] - Earnings per share for the third quarter of 2021 were ¥1.5739, slightly up from ¥1.5549 in the same quarter of 2020[25] Research and Development - Total R&D investment for Q3 2021 was ¥18,342,651.82, which is an increase of 113.36% year-on-year[6] - R&D investment accounted for 16.39% of operating revenue in Q3 2021, up by 7.63 percentage points from the previous year[6] - Research and development expenses for the first three quarters of 2021 totaled ¥46,463,175.23, significantly higher than ¥23,862,728.01 in the previous year, indicating a focus on innovation[23] - The company has a significant focus on research and development, with ongoing projects aimed at enhancing product offerings and market expansion strategies[16] Cash Flow and Assets - The cash flow from operating activities for the year-to-date period increased by 64.59%, primarily due to the expansion of business scale[7] - The net cash flow from operating activities was 85,294,228.32 RMB, an increase of 64.5% compared to 51,823,350.77 RMB in the previous year[27] - The total cash inflow from investment activities reached 3,197,962,728.20 RMB, significantly up from 845,629,967.58 RMB, marking a growth of 277.5%[27] - The cash outflow for investment activities was 3,394,265,888.24 RMB, compared to 1,596,746,049.14 RMB, resulting in a net cash flow from investment activities of -196,303,160.04 RMB[27] - The total assets at the end of Q3 2021 were ¥1,566,608,441.44, a 1.70% increase from the end of the previous year[6] - The company's cash and cash equivalents decreased to RMB 1,171,940,014.84 from RMB 1,366,464,211.43, representing a decline of about 14.2%[18] - The total liabilities as of the end of Q3 2021 amounted to ¥105,285,395.96, compared to ¥129,453,569.35 at the end of the previous year[23] Future Outlook - Future guidance indicates a cautious optimism regarding revenue growth, driven by new product launches and market penetration efforts[16] - The company has indicated plans for market expansion and new product development as part of its future strategy[24] - The company is actively exploring potential mergers and acquisitions to strengthen its market position and expand its operational capabilities[16] Shareholder Information - The company reported a total of 3,509,288 shares held by Shenzhen Yanghe Biomedical Investment Co., Ltd., making it the largest unrestricted shareholder[15] Financial Management - The company reported a financial income of ¥12,001,146.74 in the first three quarters of 2021, compared to ¥3,034,198.92 in the previous year, reflecting improved financial management[23] - The total equity attributable to shareholders of the parent company was ¥1,459,495,216.08, up from ¥1,406,015,537.73 in the previous year[23] Liabilities and Equity - The total current liabilities decreased to RMB 102,971,270.62 from RMB 128,677,351.40, a reduction of about 20.0%[19] - The total liabilities were reported at 129,453,569.35 RMB, compared to 133,618,934.22 RMB previously[31] - The total equity attributable to shareholders was 1,406,015,537.73 RMB, remaining stable compared to the previous year[31] Changes in Accounting Standards - The company implemented new leasing standards starting from 2021, affecting the financial statements[28]